Transgenomic Shares Slide 6.4 Percent on 'Disappointing' Q3 Sales | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Transgenomic were down 6.4 percent, or $.03, at $.44 in mid-afternoon trading after the company said it was “very disappointed” with its sales performance in the third quarter
 
As GenomeWeb News reported this morning, Transgenomic said third-quarter revenues decreased 26 percent as R&D spending rose 15 percent and income turned swung to a loss.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.